How to Help Your Patients Find Entresto (Sacubitril/Valsartan) in Stock: A Provider's Guide

Heart failure patients on sacubitril/valsartan need consistent access to their medication — missing doses is not a minor inconvenience when a patient has an ejection fraction below 35%. This guide provides cardiologists, internists, and primary care providers with a practical toolkit for helping patients navigate fill difficulties, insurance barriers, and pharmacy stock gaps in 2026.

Understanding the Current Landscape

The brand-to-generic transition of 2024–2025 remains the primary driver of patient fill difficulties. While no formal FDA shortage exists, patients encounter three types of problems:

Pharmacy stock gaps: Individual pharmacies carry brand or generic, but not both, and may be temporarily out of the patient's strength.

Insurance barriers: Prior authorization requirements, step therapy mandates, and formulary tier changes delay fills.

Cost barriers: Brand-name Entresto can cost $600–$700/month without insurance, and even with coverage, copays can be $100–$400/month without manufacturer savings programs.

Action 1: Prescribe the Generic Proactively

The most impactful step a prescriber can take is switching brand-specific prescriptions to generic sacubitril/valsartan. FDA-approved generic sacubitril/valsartan from multiple manufacturers (Novadoz, Camber, Ascend, Macleods) is bioequivalent to Entresto in all three strengths. Prescribing with DAW-0 (dispense as written = off, allow generic substitution) gives pharmacies maximum flexibility to use whichever manufacturer's product is on their shelf. This alone resolves most stock gap issues.

Action 2: Streamline Prior Authorization Documentation

Having a prior authorization packet ready to go for sacubitril/valsartan will dramatically cut approval wait times. Keep the following documentation on hand:

Most recent echocardiogram with LVEF measurement (especially if <40%)

NYHA functional class documentation in the chart

Documented history of ACE inhibitor or ARB trial with reason for failure or intolerance (cough, angioedema, hyperkalemia, etc.)

Letter of medical necessity template, pre-populated for sacubitril/valsartan

For plans that have both Entresto and generic sacubitril/valsartan on formulary, confirm which one is preferred — some plans now prefer the generic and will reject brand-specific prescriptions without a DAW-override.

Action 3: Know Your Local Pharmacy Landscape

Build relationships with pharmacists at the large-chain and hospital pharmacies your patients use most. When you know which pharmacies reliably stock sacubitril/valsartan, you can direct patients there first. Some hospital outpatient pharmacies and specialty pharmacies (Accredo, CVS Specialty) maintain more reliable inventory for high-demand cardiac medications.

Action 4: Point Patients to medfinder

medfinder is a service that contacts pharmacies near the patient by phone to check which ones have sacubitril/valsartan in stock and can fill the prescription. The results are texted directly to the patient. For care teams managing high volumes of heart failure patients, directing fill-difficulty calls to medfinder can significantly reduce the administrative burden on your staff while getting patients connected to available medication faster.

Action 5: Address Cost Barriers Proactively

Cost is the most common reason patients quietly discontinue or reduce sacubitril/valsartan doses. Educate your team to screen for cost barriers at every heart failure visit and have savings resources ready:

Commercially insured patients: Novartis copay card reduces cost to as low as $10/month (up to $4,100/year combined limit).

Medicare Part D patients: IRA-negotiated price of ~$295/month effective 2026; $2,000 annual OOP cap under Part D.

Uninsured/underinsured patients: Generic sacubitril/valsartan with GoodRx or SingleCare can be as low as $50/month; Novartis Patient Assistance Program available for qualifying patients.

PAN Foundation grants: Up to $2,400/year when funding is available for patients with heart failure.

Action 6: Educate Patients on Refill Timing

Advise patients to refill sacubitril/valsartan at least 7–10 days before running out. Heart failure medications should not be interrupted — and the search for a pharmacy with stock takes time. Consider transitioning stable patients to 90-day mail-order fills. Read the full provider shortage update here.